TrialLancet (London, England)2010

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.

Michaela Diamant et al.PubMed ↗Publisher ↗

No numbers read from the abstract.